招商证券(香港)：诺诚健华（09969）港股公司研究报告-Stillupsideafterapprovals

诺诚健华-B(09969) Co.announceditsBTKiorelabrutinib(orela)hasreceivedNDAapprovalsbyNMPAforr/rCLL/SLLandr/rMCL,inlinew/CMSEst. ShanghaiStockExchangeannouncedinclusionofInnocarestockintotheSouthboundTrading,effectiveonDec28,2020 WekeepSOTP-basedTPunchangedatHKD17.9,andmaintainBUYonitsmultiplecatalystsandorela’spotentialinMSspace Orelamarkeditsfirstcommercialmilestone Theapprovaloforelabrutinibisbasedontwophase2registrationalstudies,ICP-CL-00102forr/rMCL(n=106)andICP-CL-00103forr/rCLL/SLL(n=80).AtASH20i